C linical oncologists know that pain is prevalent among cancer patients and can present during any phase of illness. A meta-analysis described pain in 59% of patients in active treatment, 33% of survivors after treatment, and 64% of those with metastatic, advanced, or terminal disease.
C linical oncologists know that pain is prevalent among cancer patients and can present during any phase of illness. A meta-analysis described pain in 59% of patients in active treatment, 33% of survivors after treatment, and 64% of those with metastatic, advanced, or terminal disease. 1 Pain is not only one of the most common cancer-related symptoms but among the most feared. 2 Suboptimal pain management can lead to severe and unnecessary physical sufering, hindered relationships, and an overall decrease in patient quality of life.
Despite recognition of its importance, pain management for patients with cancer is not always adequate. In a prospective study published in 2012 that assessed more than 3,000 outpatients, 33% of cancer patients reporting pain were found to be receiving inadequate analgesia, and 23% of patients with severe pain and 27% of those with moderate pain were not receiving any analgesia. 3 A review of 26 relevant studies conducted in 2008 suggested that 43% of cancer patients had pain that was undertreated. 4 Cancer-related pain is often multidimensional, involving nociceptive and neuropathic pain, and may afect many aspects of a person's life, including their psychosocial and spiritual health. Conversely, psychological, social, and spiritual factors can afect both the patient's pain experience and its clinical manifestation; thus, pain in cancer patients can have a complex presentation. Appropriately assessing pain, developing an analgesic regimen, minimizing medication adverse efects, and optimizing patient compliance are all key components to efective pain management. Increasingly, some form of screening for substance abuse disorders is also important. In this review, we discuss the syndromes, assessment of, and treatment for cancer-related pain in the outpatient setting.
Syndromes
Cancer pain syndromes are defned by particular pain characteristics and physical symptoms that are associated with the underlying disease process or its treatments. Tese pain syndromes can be acute or chronic and are categorized according to their etiology. Cancer pain is often multifactorial and may involve the malignancy itself, oncologic treatments, as well as psychosocial and spiritual distress. One study found that 60%-65% of cancer pain is related to direct tumor involvement, 20%-25% is related to cancer treatment, and 10%-15% is unrelated to the actual cancer. 5 Malignancies can directly involve the bone, nerves, or viscera and can also produce an infammatory response that can lead to worsening pain. Pain mechanisms can be categorized as neuropathic or nociceptive; nociceptive pain is often further categorized into somatic or visceral subtypes. Somatic pain results from injury to the skin, subcutaneous tissue, bone, muscle, blood vessels, and connective tissue; it is often described as localized, con-stant, aching, and dull. Visceral pain arises from damage to organs and the lining of body cavities, and can be described as poorly localized, cramping, and deep. Neuropathic pain arises from injury to nerve tissue, and is often described as burning, shooting, and electrical. Frequently neuropathic pain persists in the absence of ongoing neural tissue injury. Allodynia (pain response to a normally innocuous stimulus) and hyperalgesia (increased pain response to a normally painful stimulus) can also occur, and severe nerve damage can result in paresthesia, numbness, weakness, and muscle wasting.
Pain is one of the most common symptoms related to cancer therapy (Table 1) . About 20% of chronic cancer pain problems are related to adverse consequences of chemotherapy, surgery, and radiation. 6 Among breast cancer survivors, 42% of patients have chronic pain. 7 Chemotherapy agents, including taxanes, vinca alkaloids, platinum-based compounds, epothilones, bortezomib, thalidomide, and lenalidomide, can lead to both acute and chronic neuropathic pain. Te incidence of chemotherapy-induced peripheral neuropathy (CIPN) ranges from 30%-40% of patients receiving chemotherapy. 8 CIPN predominantly afects the peripheral nervous system and presents as a dose-dependent, sensory polyneuropathy that often begins acutely in the hands and feet.
Surgical interventions, such as thoracotomies or mastectomies, can also lead to pain syndromes. Chronic pain was noted in 20% of women after mastectomy or lumpectomy with axillary node dissection. 9 Tis is thought to be due to intercostobrachial nerve trauma. Similarly, patients who have undergone thoracotomies or port insertions for intravenous access may develop postthoracotomy syndrome, presenting as numbness, tenderness, and burning sensations over the surgical site, likely from injury to the intercostal nerves. Radiation therapy can lead to plexopathies, enteritis, and proctitis.
Psychosocial distress exists among cancer patients and has a reciprocal relationship with physical pain. Studies of terminally ill cancer patients found that one-fourth experienced adjustment disorders and/or major depression, 10 and terminally ill cancer patients who were depressed were 4 times more likely to have a high desire for hastened death than were nondepressed patients. 11 Cancer pain has also been identifed as one of the largest contributors to emotional distress among cancer patients. 12 Conversely, psychosocial stress can exacerbate physical pain, as was elucidated by a meta-analysis of randomized controlled studies on adult cancer patients during 1966-2010 that found positive efects of psychosocial interventions on pain severity. 13 Similarly, spiritual interventions can be important for some patients. Spirituality can be defned as the way in which people seek and express meaning and purpose in life, and involves an individual's interconnectedness with oneself, others, and that which one considers signifcant and sacred.
14 Hence, it is no surprise that spiritual distress exists among cancer patients as their illness can afect their values, hopes, fears, and relationships. As their disease progresses, cancer patients may fnd themselves wrestling with existential questions related to the purpose and meaning of life, death, sickness, and sufering. Research on endstage cancer patients demonstrated a signifcant correlation between the will to live and existential, psychological, social, and physical sources of distress. 15 Oncologic pain emergencies may also arise. In particular, malignant epidural spinal cord compression is a medical emergency that afects about 5%-10% of adult solid tumor patients. 16 It can lead to permanent neurologic impairment and paraplegia if it is not diagnosed early and treated 17 Early identifcation is vital because neurologic symptoms may be irreversible by the time symptoms arise, whereas patients who are treated while still ambulatory have a 90% chance of remaining ambulatory. 18 In addition to clinical awareness, knowing when to obtain imaging studies and which imaging study to order are essential. A cancer patient with back pain and abnormal plain flms of the spine has a 70% chance of having an epidural metastasis; however, as many as 5% of cancer patients with a normal bone scan will have metastatic bony disease on MRI. 19 In cancer patients, the symptom of back pain should alert clinicians to evaluate for bone metastasis and consider obtaining appropriate imaging studies.
Assessment
Te pain assessment is a vital component of cancer pain management. A study that surveyed physicians found that 76% of physicians identifed poor pain assessment as the single most important barrier to adequate pain management. 20 An efective cancer pain assessment identifes underlying pain syndromes and mechanisms to develop the most efective treatment plan for pain control. An efective pain assessment is predicated on a trusting physicianpatient relationship and includes a detailed medical and pain history, physical exam, psychosocial and spiritual evaluation, and screen for substance abuse.
Obtaining a detailed pain history involves identifying pain characteristics, such as pain intensity, quality, location, radiation, and alleviating and aggravating factors. It is important to note temporal features (ie, acute, subacute, chronic), whether the pain is constant or episodic, and to establish a chronologic timeline of symptom presentation in the context of the underlying disease trajectory because cancer pain can be caused by either the malignancy itself or its treatments. Review of diagnostic studies can also be useful in identifying particular syndromes, and an appropriate physical exam can help identify underlying pain mechanisms. For example, decreased sensation, allodynia, hyperalgesia, or weakness may suggest neuropathic pain, whereas point tenderness over a bone may suggest malignant bony involvement. Current and previous pain management regimens should be evaluated, noting compliance, efectiveness, and adverse efects of therapies.
Validated self-reporting scales are useful tools to help characterize, rate, and monitor a patient's pain and response to therapy. Te Agency for Healthcare Research and Quality, 21 the American Pain Society 22 and the World Health Organization 23 all identify assessment of pain through patient reporting as the most important factor in determining treatment. Teir guidelines recommend using pain-rating scales in all patients who commence or change treatments in order to assess pain severity and relief. Te most frequently used validated scales include the visual analog scale (VAS), the verbal rating scale (VRS), and the numerical rating scale (NRS). 24 In cases in which communication or cognitive ability are impaired, physical and behavioral signs of discomfort (ie, facial grimacing, vocalizations, changes in interpersonal interactions, body movements) can be used to assess the presence of pain; however, these methods may be limited in their assessment of pain intensity. In these cases, the Pain Assessment in Advanced Dementia (PAINAD) scale, 25 and for children, the WongBaker Faces Pain Rating Scale, 26 can be useful. It is also important to assess the way in which pain afects various aspects of a person's life, including activities of daily living, appetite, sleep, vitality, and relationships. More comprehensive tools that evaluate these functional dimensions include the Brief Pain Inventory, 27 the Memorial Symptom Assessment Scale, 28 and the Edmonton Symptom Assessment Scale. 29 Given the reciprocal relationship between psycho-spiritual distress and physical pain, it is important for clinicians to perform an appropriate psychiatric and spiritual evaluation. While a thorough history and physical examination is the gold standard for the assessment of psycho-spiritual problems, an oncologist in a busy clinic setting might instead rely on staf-administered screening tools to provide an efective and time-efcient method to evaluate psychospiritual issues and identify patients who may beneft from further discussions, including a referral to mental health and spiritual care specialists. Useful clinical tools to assess physical and psycho-spiritual distress include the National Comprehensive Cancer Network Distress Termometer for Patients 30 and the Alberta Health Services Screening for Distress tool. 31 Spiritual health may be further evaluated using FICA (Faith/Beliefs, Importance, Community, Address in care or action) and similar clinical tools. 32 Delirium, depression, and anxiety are among the most common psychiatric problems that afict cancer patients and are interconnected with pain management. 33, 34 Te Confusion Assessment Method is a brief screening tool for delirium that has been validated in many patient populations, including patients with advanced illnesses. 35 More detailed diagnostic tools, such as the Delirium Rating Scale Revised-98 and the Memorial Delirium Assessment Scale, can be used to confrm the diagnosis of delirium and monitor changes over time. 36 It is important to be attentive to the various delirium subtypes (hypoactive, hyperactive or mixed) and identify any reversible causes, such as dehydration, electrolyte abnormalities, infection, pain, and medications (ie, opioids, benzodiazepines, anticholinergics, steroids).
interview and the SOAPP, followed by the ORT and the DIRE. 41 A treatment contract can be useful in establishing clear expectations for the physician and patient and in outlining the consequences of aberrant medication use. Such a contract may include spot urine toxicology screens, expectations for follow-up visits, management of medication supply, and requirement of joint management with a substance abuse specialist.
Treatment
Te goal of cancer-related pain treatment is to enhance patient quality of life by providing sustained and efective pain relief with tolerable side efects. Pain treatments can be categorized into pharmacologic, nonpharmacologic, and interventional therapies. Pharmacologic therapies can be further divided into opioids, nonopioids, and adjuvants. Tere exist various types of opioids, including opioid receptor agonists, partial agonists, and mixed agonists-antagonists, with the agonist agents being the most efective and commonly used for analgesia. Of the various opioid receptors, the mu receptor is the most clinically relevant in terms of analgesia and related adverse efects.
Opioid selection should be individualized. Numerous splice variants of the mu receptor gene are thought to lead to clinical variability in opioid efcacy and adverse efects. 42 When selecting an opioid, clinicians should consider patients' past experiences with opioids, including both analgesic beneft and tolerability. For opioid naïve patients, starting with one of the pure mu receptor agonists while monitoring for both clinical beneft and adverse efects would be a reasonable approach. Indeed, the most appropriate opioid for a patient is the one that works best for them. Opioids have multiple routes of administration and are produced in long-and short-acting formulations (Tables 2 and 3 ). Because opioids alter pain perception and signal transmission, they can have an analgesic efect in different types of pain syndromes, regardless of the under- 
Review
Depression can present as changes in mood, vitality, sleep, appetite, and weight, and is often linked to disease progression and diminshed quality of life. Depression screening tests that have demonstrated beneft in oncology patients include the Patient Health Questionnaire, 37 the Zung Depression Scale, 38 and the Beck Depression Inventory. 39 Te Hospital Anxiety and Depression Scale is an efcient and commonly used screening tool for anxiety among cancer patients and can also help screen for depression. 40 A medication review is important as depression can be induced by certain medications, including corticosteroids, interferon, and drugs that block estrogen receptors (ie, tamoxifen).
Screening for substance abuse in patients and their families is another important component of the pain assessment. In the context of a serious public health problem in the United States in the last 15 years -a true epidemic of prescription opioid abuse and diversion -some experts are advocating for universal precautions (eg, substance abuse risk/screening) for all patients who are being prescribed opioids. Although many cancer pain management and palliative care clinicians disagree with this strategy for their patients, oncologists should at least be aware that some state medical boards and other agencies have taken fairly strong stances on this issue. Optimal evaluation and management of substance abuse involves a multidisciplinary team that includes social workers, psychologists, psychiatrists, chaplains, and mental health professionals who specialize in substance abuse. Screening tools, including the Screener and Opioid Assessment for Patients with Pain (SOAPP), the Opioid Risk Tool (ORT), and the Diagnosis, Intractability, Risk, and Efcacy (DIRE) inventory, can assist in evaluating the likelihood of inappropriate drug use in chronic pain patients. A comparative study on common screening methods for predicting aberrant drugrelated behavior in chronic pain patients who received opioids demonstrated the highest sensitivity for the clinical lying pathophysiology. 43 Most opioids have similar initial adverse efects, such as sedation and nausea, which typically resolve after a few days. Other, more serious adverse efects that clinicians and patients should be aware of include confusion, nightmares, hallucinations, urinary retention, myoclonus, dizziness, and dysphoria. In general, opioids should be used cautiously in patients who are in acute pain with impaired ventilation, bronchial asthma, or raised intracranial pressure; however, the same caveats should not typically limit dose titrations in chronic cancer pain management. 44 In the case in which an opioid is inefective despite increased doses or its side efects become unmanageable, it would be appropriate to rotate to a diferent opioid.
Commonly used pure mu receptor agonists include morphine, hydromorphone, oxycodone, hydrocodone, fentanyl, and methadone. Although morphine was traditionally considered the gold standard for opioids, there does not seem to be a demonstrable diference in efectiveness among the diferent opioids. 45 Hydromorphone is a derivative of morphine that is about 5-10 times more potent than morphine. Oxycodone is a synthetic opioid that is slightly more potent than oral morphine and seems to have similar adverse efects to morphine and hydromorphone. Hydrocodone is found in combination products with acetaminophen and ibuprofen, and a liquid cough formulation exists in combination with homatropine. Fentanyl is a highly lipid-soluble opioid that has a long-acting transdermal formulation that provides an alternate route of administration in patients for whom ingestion of oral medications may be difcult or impossible. Te absorption of transdermal fentanyl can be afected by edema, body temperature, and fat content. 46 Although other opioids have active metabolites that can cause neurotoxicity in the setting of renal impairment, fentanyl and methadone are safer alternatives in patients with renal failure because they do not have active metabolites.
Long-acting opioids, or controlled-release opioids, can provide greater pain relief in patients whose pain is not optimized with short-acting opioid formulations. Controlled-release opioids should not be used in opioid naive patients, and clinicians and patients should be aware of the associated risks of opioid addiction and misuse, which can lead to overdose and death. Tere are various controlled-release opioid formulations available (Table 3) , including hydromorphone, oxycodone, and morphine. In patients who have difculty swallowing, 2 morphine formualtions, Avinza and Kadian, would be of beneft as they can be sprinkled, whereas other controlled-release opioids should not be crushed. Another controlled-release opioid, oxymorphone (Opana ER), should be taken 1 hour before or 2 hours after meals, because its peak varies with food intake.
Methadone acts as an opioid receptor agonist and an NMDA (N-methyl-d-aspartate) receptor antagonist, and also blocks the reuptake of serotonin and norepinephrine. Given its various mechanisms of action, methadone can be efective in multifaceted pain syndromes involving both somatic and neuropathic pain, although there are conficting results in neuropathic pain studies. 47 ,48 Given methadone's variable and long half-life, clinicians should be watchful for adverse events as a result of drug accumulation. 49 Methadone's pharmacokinetics can be especially variable in cancer patients because methadone binds avidly to alpha1-glycoproteins, the levels of which are increased in cancer patients, which can lead to a decrease in unbound methadone and a delayed onset of efect. 49 Because methadone is metabolized primarily by CYP3A4, clinicians should be aware of other medications that may inhibit or induce the CYP3A4 enzyme. Methadone can prolong the QTc interval, so QTc monitoring may be warranted in appropriate settings. 50 Recent guidelines suggest that methadone should be prescribed only by clinicians who are familiar with its use, such as palliative medicine, pain, and addiction medicine specialists. 50 Tere are other weaker agents, such as codeine and tramadol. Codeine is an opioid alkaloid whose action is dependent on its metabolism to the active form, morphine. Because of codeine's genetic variability in its rate of metabolism, its use should be individualized. 51 Tramadol is a synthetic analog of codeine that has shown efcacy in neuropathic pain, 52 but has no anti-infammatory activity. It can increase the risk of seizures and serotonin syndrome because it is also a monoamine reuptake inhibitor. Unlike the stronger opioids, there is a "ceiling efect" for these medications, that is, above a certain threshold dose, there is no additional analgesic efect but there is still the potential for adverse efects. 
Commonly used nonopioid medications include nonsteroidal anti-infammatory drugs (NSAIDs) and acetaminophen. NSAIDs can be quite efective in controlling pain caused by infammatory processes and/or bone metastasis but can have potential adverse efects, such as gastrointestinal bleeding, platelet dysfunction, and renal failure. 53 Patients with a history of gastritis or gastrointestinal bleeds should either be on a combination of a nonselective NSAID with a proton pump inhibitor or switched to a selective cyclooxygenase (COX2) inhibitor. 54 It is important to note that COX2 inhibitors do not protect against renal failure and may present an increased risk of thrombotic cardiovascular events. 55 Acetaminophen can also be an efective analgesic for cancer pain, but should be used cautiously in patients with hepatic impairment.
Adjuvant analgesics are medications that are not primarily indicated for pain management but can be an efective analgesic in various pain syndromes. Commonly used adjuvants that are used to treat neuropathic pain include anticonvulsants, antidepressants, corticosteroids, ketamine, and cannabinoids. Gabapentin is the most commonly used anticonvulsant for neuropathic pain and can have an added analgesic efect when used in combination with tricyclic antidepressants such as nortriptyline. 56 Its main side efects are somnolence and dizziness. Whereas gabapentin's bioavailability decreases at higher doses (60%-80% percent bioavailability at 100 mg every 8 hours vs 27% at 1600 mg every 8 hours), the gabapentin analog pregabalin is linearly absorbed in all doses. 57, 58 Hence, pregabalin may be a more efective alternative to gabapentin in patients requiring higher doses of the medication. Serotonin norepinephrine reuptake inhibitors, such as venlafaxine and duloxetine, are recommended along with gabapentin and pregabalin as frst-line treatments for diabetic neuropathic pain. 59 Tricyclic antidepressants can be useful for neuropathic pain with the added beneft of improving mood and sleep; however, their use may be limited in the elderly because of its anticholinergic efects and it should also be avoided in patients with glaucoma and those who are suicidal. 60 Corticosteroids reduce infammation, inhibit prostaglandin production, and reduce neuronal excitability, which makes it particularly useful in metastatic bone pain and neuropathic pain caused by spinal cord or nerve plexus compression. 61 Corticosteroids also provide the additional benefts of improved appetite, malaise, and nausea. Transdermal lidocaine has been approved by the US Food and Drug Administration for postherpetic neuralgia, but may also be efective in other neuropathic pain conditions, including postmastectomy pain syndrome and diabetic neuropathy. 62 Ketamine is a pure NMDA antagonist that has been shown to improve neuropathic cancer pain; 63 potential adverse efects include sedation, delirium, and hallucinations, especially at higher doses. Although data in cancer pain is limited, cannabinoids have been shown to be of beneft in neuropathic pain in HIV-positive patients. 64 In addition to NSAIDs and corticosteroids, bonemetabolism modifying agents can help relieve cancerrelated bone pain. Bisphosphonates inhibit osteoclast activity and can provide relief from metastatic bone pain. Te American Society of Clinical Oncology recommends using pamidronate or zoledronic acid; however, these medications should be avoided in the setting of renal failure, and patients should be aware that both medications can initially worsen the pain due to an acute phase reaction. 65 Te RANK-L inhibitor denosumab prevents bone resorption and osteoclast maturation and activation. Denosumab can improve bone pain, is not renal toxic, and causes fewer episodes of acute phase reactions compared with zolendronic acid. 66 Calcitonin reduces bone resorption, and although the evidence is scarce for its efectiveness in treating cancer-related bone pain, it is generally well tolerated. 67 Various nonpharmacologic modalities can also help treat cancer-related pain. Tere are many studies supporting the use of cognitive and behavioral therapy (CBT) for chronic pain management; 68 however, results are mixed for the efectiveness of CBT in cancer-related pain. 69, 70 Acupuncture, therapeutic massage and exercise can also be efective in managing all types of cancer-related pain. 71, 72 Transcutaneous electrical nerve stimulation, topical heat, and ice therapy are other topical therapies that can provide pain relief with few adverse efects. Mind-body interventions such as biofeedback, diversion of attention, relaxation breathing, meditation, and music and art therapy can all be useful in managing cancer pain. 73 Interventional therapies are also available to treat cancer-related pain, and are particularly efective in severe cases that are refractory to systemic analgesics and cases in which intolerable side efects limit medication use. Celiac plexus blocks can provide long-lasting beneft for 70%-90% of patients with pancreatic and other abdominal malignancies, 74 and hypogastric plexus blocks can be efective in chronic cancer-related pelvic pain. 75 Intrathecal pumps deliver opioids directly into the subarachnoid space, achieving equianalgesic efect at much lower doses than do systemic administrations, thereby decreasing the risk of opioid dose-related adverse efects.
External beam radiation can be an efective treatment option for localized metastatic bone pain. It provides pain relief in 50% and 75% of patients at 2 and 4 weeks, respectively, after treatment, and for most patients, pain relief lasts for 3 months. 76 Single fraction radiation is recommended over multiple-fraction regimens for the treatment of metastatic bone pain. 77 Tere is no diference in the duration of or time to pain relief between single large fraction radiation and conventional radiation treatments involving mul- 78 Patients should also be aware of a possible transient increase in pain at the treatment site, which may be decreased with NSAIDs or corticosteroids. 79 In cases in which optimal pain relief is not achieved despite medication and interventional therapies, surgical procedures, such as cordotomy and myelotomy, may be of beneft. Cordotomy is indicated for unilateral medically intractable cancer pain below the level of C5 and can provide immediate pain relief in over 90% of patients; although, the analgesic efect decreases to 40% after 1 year. 80 Vertebroplasty can be efective in vertebral compressions from bone metastasis, 81 and kyphoplasty has been demonstrated to be safe and efective in bone pain associated with multiple myeloma. 82 Case reports have suggested a high success rate in pain control for patients with malignant compression fractures and indicate pain relief within 48 hours after vertebroplasty. 83 Tere are a number of barriers to efective cancer-related pain management, including physician-related barriers, patient-related barriers and society and tradition-related barriers. 84 A review of empirical research on these barriers in the literature identifed the most signifcant patientrelated barriers were patient reluctance to report pain and adhere to treatment recommendations. 85 Te most prominent physician-related barriers were insufcient physicians' knowledge about cancer pain management, inadequate patterns of pain assessment, and inadequate opioid prescription. A large multicenter study that surveyed physicians identifed a number of critical barriers to efective cancer pain management (Table 4) with 76% of physicians designating poor pain assessment as the single most important barrier to adequate pain management. 86 
Summary
Uncontrolled pain is one of the most feared and debilitating symptoms among cancer patients, and many suffer unnecessarily from suboptimal pain control. Pain can afect all aspects of a patient's life, and each individual has a unique experience in how they manage, cope and respond to their pain and related treatments. Hence, achieving adequate pain relief involves a proper assessment of psychosocial, spiritual and physical pain issues, matched with an individualized treatment plan involving pharmacologic, nonpharmacologic and procedural therapies when appropriate. Indeed, the optimal context in which pain management occurs is within a multidisciplinary health care team, involving oncologists, pain management and palliative medicine specialists, nurses, chaplains, social workers, physical and occupational therapists, complementary and alternative medicine specialists, psychiatrists, psychologists, surgeons, and radiologists. Providing adequate pain relief can help ease the overall burden of disease among oncology patients while helping them tolerate cancer-directed therapies and achieve the most optimal quality of life throughout all phases of the disease process.
